fig2
![Proteasomal adaptations to FDA-approved proteasome inhibitors: a potential mechanism for drug resistance?](https://image.oaes.cc/777b1aec-4767-48e3-848e-0c11ee5b14c2/4081.fig.2.jpg)
Figure 2. FDA-approved proteasome inhibitors. Bortezomib and ixazomib contain a boronic acid pharmacophore, while a tetrapeptide carfilzomib has an epoxyketone pharmacophore.
Figure 2. FDA-approved proteasome inhibitors. Bortezomib and ixazomib contain a boronic acid pharmacophore, while a tetrapeptide carfilzomib has an epoxyketone pharmacophore.
All published articles will preserved here permanently:
https://www.portico.org/publishers/oae/